>
Everything I Warned You About Just Happened... All in One Week
Your Grief, My Grief, Our Grief in the Loss of a Loved One
Vance: Federal Government Has Identified $230 Billion In Fraud Since March
Saudi Arabia's $5 Oil Detour Is Expensive... But Worth It
What could possibly go wrong? Scientists use AI to design new viruses
Dual-motor suitcase drive underpins 3,000-hp hypercar
DoorDash Wins Federal Approval To Fly Its Own Delivery Drones
Shade-Resistant Solar Cells Retain 97% Efficiency After 2,000 Hours of Testing
20 Ancient Engineering SECRETS
Stonehenge Was Reanalyzed by AI -- And the Findings Are Hard to Explain
After Years Of Delays, Aptera Is Finally Preparing To Build Customer Cars
'When you kill it, it doesn't die': the jellyfish that has cracked the secret of immorta
Archer Aviation debuts Halo autonomous VTOL, Thunder's commercial twin
US Telecoms Slide On Starlink Mobile Threat; Bernstein Sees It As A "Jab, But No Knockout Yet**

Like the horse of Troy, scientists at the Technion have developed a way to sneak synthetic cells right into tumor tissue, where they then begin producing cancer-fighting proteins from the inside. The technique was tested in both cell cultures and in mice, and found to be an effective treatment in both cases.
Cancer cells thrive thanks to some robust defense mechanisms, so finding ways to get past them is a key area of research. In the past, scientists have sent gold nanoparticles inside tumors by hitchhiking on white blood cells, before heating the gold with near-infrared light to kill the cancer from within. Others examined the possibility of administering a "prodrug" that remained inactive until it detected cancer markers, and then began producing drugs from inside the tumor.
The new work follows a similar function as the latter. The Technion scientists loaded molecular machines inside lipid-based particles that resemble biological cell membranes, creating what they call "nano-factories." Once they're activated by sensing the presence of abnormal cells, these particles kick into gear, producing specific therapeutic proteins and pulling the energy and building blocks they need from the tumor tissue around them.
"By coding the integrated DNA template, the particles we developed can produce a variety of protein medicines," says Avi Schroeder, one of the lead researchers on the study. "They are modular, meaning they allow for activation of protein production in accordance with the environmental conditions. Therefore, the artificial cells we've developed at the Technion may take an important part in the personalized medicine trend – adjustment of treatment to the genetic and medical profile of a specific patient."